LBX(SH:603883)2019-10-30 16:00Financial Performance - Net profit attributable to shareholders rose by 21.44% to CNY 394,275,646 for the year-to-date period[6] - Operating revenue grew by 23.59% to CNY 8,369,710,335 for the year-to-date period[6] - Basic earnings per share increased by 21.05% to CNY 1.38[6] - The weighted average return on equity rose by 0.94 percentage points to 12.12%[6] - Total revenue for Q3 2019 reached RMB 2,836,194,792, an increase of 21.5% compared to RMB 2,334,723,994 in Q3 2018[32] - Net profit for the first nine months of 2019 was RMB 902,614,326, up from RMB 447,042,347 in the same period of 2018, representing a growth of 101.9%[31] - The net profit for Q3 2019 reached CNY 66,394,372, compared to CNY 15,036,703 in Q3 2018, indicating a significant increase of approximately 341.5%[36] - The total profit for the first three quarters of 2019 was CNY 630,296,383, up from CNY 95,051,745 in the same period of 2018, reflecting a growth of approximately 563.5%[36] Assets and Liabilities - Total assets increased by 10.18% to CNY 9,348,172,733 compared to the end of the previous year[6] - The company's total current assets amounted to 4.798 billion RMB, an increase from 4.311 billion RMB at the end of 2018, representing a growth of approximately 11.3%[25] - The company's total liabilities amounted to 5.637 billion RMB, compared to 5.115 billion RMB at the end of 2018, showing an increase of about 10.2%[27] - The company's goodwill increased to 2.130 billion RMB from 1.987 billion RMB at the end of 2018, representing a growth of approximately 7.2%[26] - The company's total liabilities reached ¥4,945,869,129, indicating a stable financial position with no significant changes from the previous year[44] - Total liabilities amounted to ¥5,115,443,386, with total equity at ¥3,369,331,673, resulting in total assets of ¥8,484,775,059[45] Cash Flow - Net cash flow from operating activities increased by 20.42% to CNY 707,269,166 for the year-to-date period[6] - Cash inflow from operating activities for the first three quarters of 2019 was CNY 9,276,519,496, an increase from CNY 6,739,964,177 in the previous year, reflecting a growth of approximately 37.5%[39] - Cash outflow from operating activities for the first three quarters of 2019 totaled CNY 8,569,250,330, compared to CNY 6,152,608,520 in the same period of 2018, indicating a rise of about 39.2%[39] - The net cash flow from operating activities for Q3 2019 was ¥600,086,816, a significant increase from ¥247,729,231 in Q3 2018, representing a growth of approximately 142.5%[42] - The company reported a total cash outflow from investment activities of CNY 493,803,752 in Q3 2019, down from CNY 900,796,183 in the same period last year[40] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,268[8] - The largest shareholder, Laobaixing Pharmaceutical Group Co., Ltd., holds 34.61% of the shares[8] - The company reported a total owner's equity of 3.711 billion RMB as of September 30, 2019, compared to 3.369 billion RMB at the end of 2018, reflecting an increase of approximately 10.1%[27] Store Operations - The company opened 536 new stores during the reporting period, including 389 direct-operated stores and 147 acquired stores, while closing 69 stores[14] - The company has a total of 3,756 direct-operated stores and 1,052 franchise stores as of September 30, 2019[14] Government Subsidies - The company received government subsidies amounting to CNY 30,261,466.92 for the year-to-date period[7] - The company confirmed government subsidies amounting to CNY 10,113,936 during the reporting period[11] Investment Activities - The company reported a significant increase in long-term equity investments, totaling CNY 11,157,346, an increase of 372.22% compared to the previous period[11] - The company signed an equity transfer agreement to acquire 51% of Shanxi Huqiang Baihui Pharmaceutical Chain Co., Ltd. for a transfer price of 110.925 million RMB, with the restructuring currently in progress[22] - The company completed the acquisition of 24 stores from Guangxi Guangpu Pharmaceutical Co., Ltd. at a cost of 38.5 million RMB, with 23 stores delivered in July 2019 and the remaining store delivered in September 2019[22]